<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00470951</url>
  </required_header>
  <id_info>
    <org_study_id>NCCCTS-06-179</org_study_id>
    <nct_id>NCT00470951</nct_id>
  </id_info>
  <brief_title>Randomized Prospective Trial for Laparoscopic vs Open Resection for Rectal Cancer</brief_title>
  <acronym>CTS-179</acronym>
  <official_title>A Comparison for Laparoscopically Assisted and Open Surgery for Advanced Rectal Cancer After Preoperative Chemoradiation- Randomized Prospective Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators designed the randomized prospective trial of comparing open and&#xD;
      laparoscopic resection in locally advanced rectal cancer after preoperative chemoradiation in&#xD;
      order to determine the oncologic and functional efficacy of laparoscopic rectal resection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Title: A comparison for laparoscopically assisted and open surgery for advanced rectal&#xD;
           cancer after preoperative chemoradiation - randomized prospective trial&#xD;
&#xD;
        2. Principal investigator: Jae Hwan Oh Co-investigator: Seung Yong Jeong, Sung Bum Kang,&#xD;
           Hyo Seong Choi, Seok-Byung Lim&#xD;
&#xD;
        3. Purpose of the study: To compare efficacy of laparoscopic and open resection for locally&#xD;
           advanced rectal cancer after preoperative chemoradiation&#xD;
&#xD;
        4. Specific aims&#xD;
&#xD;
             1. comparison of oncologic outcomes&#xD;
&#xD;
             2. comparison of quality of life&#xD;
&#xD;
             3. comparison of anorectal function&#xD;
&#xD;
        5. Materials Rectal cancer &lt;9cm from anal verge, measured by rigid sigmoidoscopy&#xD;
           histologically proven adenocarcinoma locally advanced (T3), determined by CT,&#xD;
           transrectal ultrasonography, MRI without any contraindication for general&#xD;
           anesthesia,operation and chemoradiation Completion of preoperative chemoradiation&#xD;
&#xD;
        6. Statistics&#xD;
&#xD;
             1. Sample size calculation for non-inferiority trial: 340&#xD;
&#xD;
             2. Disease free survival: Log-rank test,Cox regression analysis&#xD;
&#xD;
             3. QOL and anorectal function: Repeated measured ANCOVA&#xD;
&#xD;
        7. Methods&#xD;
&#xD;
             1. operation time of operation : 6-8 weeks after end of preoperative chemoradiation&#xD;
                surgical technique standard total mesorectal excision and high ligation of inferior&#xD;
                mesenteric vessels&#xD;
&#xD;
             2. preoperative chemoradiation chemotherapy: 2 cycles of 5-FU (400 mg/m2/day) + LV (20&#xD;
                mg/m2/day) IV bolus, for 3 days in 1st &amp; 5th wks of RT or Capecitabine 825 mg/m2&#xD;
                p.o. bid during RT RT:45 Gy/ 25 fractions to the pelvis, 5.4 Gy/ 3 fractions boost&#xD;
                to the primary tumor over 5.5 wks&#xD;
&#xD;
             3. postoperative chemotherapy 4 cycles of 5-FU (400 mg/m2/day) + LV (20 mg/m2/day) IV&#xD;
                bolus, for 5 days, 4 wks interval&#xD;
&#xD;
             4. oncologic outcomes&#xD;
&#xD;
                  1. Short-term outcomes Surgical length of incision op time blood loss&#xD;
                     intraoperative complications conversion rate Pathological resection margins&#xD;
                     (proximal, distal, circumferential) number of harvested lymph nodes length of&#xD;
                     resected bowel tumor regression grade (Dworak's grading) TNM staging&#xD;
                     Perioperative recovery duration of use of parenteral narcotics initiation of&#xD;
                     peristalsis initiation of oral intake duration of hospital stay 30-day&#xD;
                     postoperative mortality morbidity&#xD;
&#xD;
                  2. Long-term outcomes Primary end point Disease free survival (3 years after&#xD;
                     surgery) Secondary end points Overall survival Local recurrence Distant&#xD;
                     metastasis Port-site and wound site recurrence&#xD;
&#xD;
             5. Quality of life Urinary function Duration of urinary catheterization Residual urine&#xD;
                volume at discharge International Prostate Symptom Score (IPSS) Male sexual&#xD;
                function International Index of Erectile Function (IIEF) Female sexual function&#xD;
                Female Sexual Function Index (FSFI) QOL assessment EORTC QLQ C30 EORTC QLQ CR38&#xD;
&#xD;
             6. Anorectal function Anorectal manometry Maximum Resting Pressure Maximum Squeezing&#xD;
                Pressure High Pressure Zone Sphincter Length Sensory Threshold Rectal Capacity&#xD;
                Rectal Compliance Rectoanal Inhibitory Reflex Fecal Incontinence Severity Index&#xD;
                (FISI)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2006</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anorectal function</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 year, 5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>preop, postop 3mo, posop 1 yr, 3yr, 5yr</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Immunologic response</measure>
    <time_frame>preop, postop 2hr, postop 1day, 5day</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>open rectal resection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>conventional open resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>laparoscopic rectal resection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>laparoscopic rectal resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>open rectal resection</intervention_name>
    <description>open rectal resection</description>
    <arm_group_label>open rectal resection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laparoscopic rectal resection</intervention_name>
    <description>laparoscopic assisted rectal resection</description>
    <arm_group_label>laparoscopic rectal resection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Mid to low rectal cancer (within 9cm from AV, measured by RS)&#xD;
&#xD;
          -  Histologically proven adenocarcinoma&#xD;
&#xD;
          -  Locally advanced (T3, determined by CT, MRI and TRUS)&#xD;
&#xD;
          -  Completion of preoperative chemoradiation&#xD;
&#xD;
          -  Age: 18-80&#xD;
&#xD;
          -  Hb ≥ 10g/dl, WBC≥ 3,000/mm3, Plt≥ 100,000/mm3&#xD;
&#xD;
          -  Cr ≤ 1.5 mg/dl&#xD;
&#xD;
          -  Adequate cardiopulmonary function&#xD;
&#xD;
          -  Informed consent from patient or patient's relative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastasis in liver, lung, brain, bone, paraaortic LN, subclavicular LN, inguinal LN&#xD;
&#xD;
          -  Second primary malignancy (except CIS of the cervix or adequately treated skin cancer&#xD;
             or prior malignancy treated more than 5 years ago without recurrence)&#xD;
&#xD;
          -  Cardiopulmonary dysfunction&#xD;
&#xD;
          -  Active, uncontrolled infection&#xD;
&#xD;
          -  Active, uncontrolled psychosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae Hwan Oh, M.D., ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center, Korea</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>May 7, 2007</study_first_submitted>
  <study_first_submitted_qc>May 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2007</study_first_posted>
  <last_update_submitted>August 16, 2012</last_update_submitted>
  <last_update_submitted_qc>August 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Seung Yong Jeong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>rectal cancer</keyword>
  <keyword>laparoscopic assisted resection</keyword>
  <keyword>open resection</keyword>
  <keyword>preoperative chemoradiation</keyword>
  <keyword>randomized trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

